Key result
Recent advances in the understanding, diagnosis, and classification of pulmonary arterial hypertension, along with newer drugs, have significantly improved patient quality of life and mortality.
Answers are grounded in this paper and cite their sources.
Recent advances in PAH therapies have significantly improved patient quality of life and mortality.
Pulmonary arterial hypertension (PAH), a rare disease involving the pulmonary vascular circuit, is defined as an elevation in pulmonary arterial pressures and is characterized by symptoms of dyspnea, chest pain, and syncope. If left untreated, the disease carries a high mortality rate, with the most common cause of death being decompensated right heart failure. Over the past 5 years, there have been significant advances in this field in regards to understanding the pathogenesis, diagnosis, and classification of PAH. The availability of newer drugs has resulted in a radical change in the management of this disease with significant improvement in both quality of life and mortality. Ongoing research promises to lead to a more comprehensive understanding of the genetics, etiology, and pathogenesis of pulmonary arterial hypertension, which may ultimately translate into more effective therapeutic options.
No takes yet. Share an insight, caveat, or question.
LaRaia et al. (2007) conducted a review in Pulmonary arterial hypertension. Recent advances in the understanding, diagnosis, and classification of pulmonary arterial hypertension, along with newer drugs, have significantly improved patient quality of life and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: